Contact Us
|
Careers
|
Menu
Home
About Us
Management Team
Board of Directors
Contact Us
Our Pipeline
Pipeline Overview
Encorafenib
Binimetinib
ARRY-797
ARRY-382
Other Programs
Discovery Collaborations
Discovery Platform
Become a Collaborator
Publications
Investors
Stock Information
News & Events
Financials
Corporate Governance
Shareholder Services
> EXPLORE OUR PIPELINE
For Patients
BRAFTOVI
®
in combination with MEKTOVI
®
approved in the U.S.
> Product website
Learn More
Find out more about the Phase 3 BEACON CRC trial
> Learn More
Latest News
03/18/2019
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal
»
03/05/2019
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
»
02/21/2019
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
»
> ALL NEWS
